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Highly Active Antiretroviral Therapy (HAART) has forever changed the outcome of HIV infection, transforming a terminal
syndrome that ravaged the immune system into a manageable chronic viral infection. However, the impact of HIV and
HAART on pediatric populations has been studied less in detail than in adults. In this article, Selvaraj et al. report their
observation on the impact of HIV infection and therapy on a cohort of children, focusing on innate immunity. Their data
shows that in this population, HIV cripples dendritic cells, and that HAART regimen does not seem to fully reconstitute that
damage. The data will be of interest to both immunologists and clinicians.
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Abstract
Understanding the defects in innate immunity associated with perinatal HIV
infection is a prerequisite for effective antiretroviral treatment. We therefore
compared the innate immune response [dendritic cell (DC) phenotype and
function] in peripheral blood by flow cytometry at baseline and 12 months in
HIV-infected children to determine the defect associated with perinatal HIV
infection. As compared with controls, patients had decreased numbers of total
DCs including plasmacytoid (p)DCs and myeloid (m)DCs and impaired function
based on induction of maturation markers (CD83, CD80, CCR7) and cytokines
tumor necrosis factor-a and interferon-a (exclusive to pDC) upon stimulation with
the TLR7/8 agonist Resiquimod. These abnormalities were evident in all three
CD4 immune categories and persisted over 12 months; pDC function worsened in
HIV+ children without treatment and improved slightly in those on highly active
antiretroviral therapy (HAART). In conclusion, a majority of perinatally HIV-infected
older children without HAART remain clinically stable in the short term, but have
demonstrable immunologic abnormalities indicative of defects in the innate
immune system. Children initiated on HAART showed improvement in CD4
counts but did not show improvement in DC function over the short term.
Introduction
HIV infection is associated with activation of immune
responses, as well as a gradual loss of immune function
and increased susceptibility to opportunistic infections.
Patients with HIV infection at both early and late stages
show immunoregulatory defects that precede CD4 T-cell
depletion (Fauci, 1993; Levy, 1993). While the loss of
adaptive HIV-specific immune responses is an area of active
investigation in HIV research, the potential role of the innate
immune response in children is largely unknown. A recent
review by Borrow et al. (2010) has emphasized the impor-
tance of innate immunity and the role of dendritic cells (DCs)
in the control of HIV/AIDS. The course of perinatal HIV
infection is rapid, with 50% of infected infants dying before
the age of 2 years (Devi et al., 2009). Hence, it is of interest
to investigate phenotypic and functional changes in DC
subsets associated with disease progression and immune
reconstitution in children receiving suppressive highly active
antiretroviral therapy (HAART).
DCs constitute a heterogeneous population of antigen
presenting cells that are critical for bridging the innate and
the adaptive immune responses. DCs are found virtually in
every tissue and organ. In the peripheral blood, two major
DC populations can be identified: CD11C+ myeloid DCs
(mDCs) and CD123+ plasmacytoid DCs (pDCs) (Siegal
et al., 1999; Banchereau et al., 2000; Liu, 2005; Zhang &
Wang, 2005; Cao & Liu, 2007). The chief mechanism of
pathogen recognition by DCs is via an evolutionarily
conserved system of Toll-like receptors (TLRs), all of which
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share an interleukin-1 (IL-1) receptor-like structural motif.
mDCs and pDCs have different patterns of TLR expression.
mDCs express TLR1–TLR6, TLR8, TLR10 and, possibly,
TLR7, while pDCs express TLR1, TLR6, TLR10, and very
high levels of TLR7 and TLR9 (Jarrossay et al., 2001;
Kadowaki et al., 2001; Krug et al., 2001; Ito et al., 2002). In
response to viral infections, both DC populations are
involved in the generation of innate and acquired immune
responses through secretion of type I interferons (IFN),
tumor necrosis factor-a (TNF-a) and IL-12. Mimicking viral
infections, resiquimod (RSQ) induces the production of IL-6,
TNF-a and IFN-a from DCs. In addition, RSQ directly
activates innate immune responses through an MyD88/
TLR7-dependent pathway (Hemmi et al., 2002).
Several studies have shown that, during HIV infection,
both DC subsets are substantially reduced in patients’ blood
(Macatonia et al., 1990; Grassi et al., 1999; Feldman et al.,
2001; Soumelis et al., 2001; Chehimi et al., 2002; Barron
et al., 2003; Donaghy et al., 2003). In some, this decrease
correlated with plasma viral load and was partially restored
following HAART (Feldman et al., 2001; Soumelis et al.,
2001; Barron et al., 2003). However, it remains unclear
whether DC functions recover following suppressive HAART
in HIV-infected children.
The main goal of the present study was to evaluate
phenotypic and functional properties of the two major
subsets of DCs in relation to immunological status of
children with perinatally acquired HIV infection, and to
evaluate immunologic changes over time in both untreated
children and those initiated on HAART.
Materials and methods
Study subjects
Sixty-two HIV-1-infected treatment-na€ıve children attending
government ART clinics in Chennai were enrolled in the
study. Informed consent was obtained from their parents or
legal guardians. They were followed up at 3-month intervals
with clinical and laboratory evaluation up to 1 year. Nine
patients were started on HAART (Lamivudine + stavudine
with Nevirapine or Efavirenz) after baseline blood collection
and continued therapy without modifying the regimen over
a1-year follow-up period. Twenty age-matched healthy
children served as controls. Venous blood was collected in
heparinized vacutainers and processed for DC assays.
Viral load
Viral load measurements were performed on plasma sam-
ples from HIV-infected children at baseline, 6 months and
1 year using the standard Cobas Amplicor HIV-1 Monitor
Test, v1.5 (Roche Diagnostic Systems) following the man-
ufacturer’s protocol.
Whole blood – DC assay
Staining was performed on heparinized blood as described
(Ida et al., 2006). Briefly, 180 µL whole blood was added
to 20 lL R5 medium (5% pooled human AB serum, 1%
HEPES buffer, 100 units mL1 penicillin and 100 µg mL1
streptomycin in RPMI 1640) containing 10 µM RSQ
(stimulated cultures) or only R5 medium (unstimulated
cultures). Cultures were set up in ventilation-capped 5-mL
polystyrene round-bottomed plastic tubes. Tubes were
incubated at 37 °C in a humid, 5% CO2 atmosphere at a
5° slant.
Intracellular cytokine assay
After 1 h of incubation, Brefeldin A was added at a final
concentration of 10 µg mL1 and incubation was contin-
ued for an additional 2 h. Following incubation, surface
staining was performed by adding the following antibody
cocktails: Lineage-1 fluorescein isothicyanate (FITC),
CD123/CD11c phycoerythrin (PE) and Human leucocyte
antigen-DR (HLA-DR) peridinin chlorophyll protein
(PerCP). Tubes were vortexed and incubated at room
temperature for 30 min in the dark. After incubation, red
cells were lysed using BD FACS lysing solution followed
by washing with 2 mL wash buffer. Cells were permea-
bilized in 200 lL cytofix/cytoperm buffer for 20 min at
4 °C. Subsequently, samples were washed twice with
1 mL permeablization buffer. Anti-human TNF-a allophy-
cocyanin (APC) (1 : 200) and anti-human IFN-a Alexa
fluor-647 (1 : 400) antibodies diluted in permeablization
buffer were added at 30 lL per tubes and samples were
incubated for 30 min in the dark at 4 °C. Samples were
washed twice with 1 mL permeablization buffer. Cell
pellets were then resuspended in 200 lL 1% paraformal-
dehyde and stored in the dark at 4 °C prior to flow
cytometric analysis.
Surface staining
After 5 h incubation, RSQ-stimulated and unstimulated
whole blood cultures were subjected to surface staining by
adding the following antibody cocktails: Lineage-1 FITC,
CD11c/CD123 APC, HLA-DR PerCP and maturation/
activation markers (CD80/CD83/CCR7) PE. Tubes were
vortexed and incubated at room temperature for 30 min.
After incubation, red cells were lysed using a BD lysing
solution followed by washing with 2 mL wash buffer. Cell
pellets were resuspended in 200 lL 1% paraformaldehye
and stored in the dark at 4 °C prior to flow cytometric
analysis.
Acquisition was performed on a FACS-Calibur machine
using CELLQUESTPRO software and analysed using FLOWJO
software version 7.1.3. Figure 1 shows the gating strategy
used to detect cytokine production and expression of
maturation factors by DC subsets in whole blood.
Statistical analysis
Statistical analysis was performed using ANOVA and a
general linear model with planned contrasts was used to
compare CD4 and viral load changes over time. P values
< 0.05 were considered significant. SAS version 9.1 was
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used for analyses; Sigma plot (version 11.0) was used to
plot graphs.
Results
Characteristics of the patient population
Sixty-two HAART na€ıve children (28 males/34 females)
with ages ranging from 9 months to 13 years, and median
body mass index of 14.4 (6.4–24.1) were included in the
study. At entry, CD4 counts in the study subjects ranged
between 5 and 44% (median 23%) and plasma HIV-RNA
between 4490 and > 750 000 (median 89 200) copies
per mL. Patients were classified into age-specific immune
categories based on their CD4 count at the time of entry
into the study: immune category 1 (IC-1) [CD4% > 25,
n = 20, (32.25%)], IC-2 [CD4% 15–25, n = 33 (53.23%)]
and IC-3 [CD4% < 15, n = 9 (14.52%)] (CDC, 1994). Nine
patients (five with CD4 < 15%, four with CD4 ≥ 15%)
were started on HAART (Lamivudine + stavudine with
Nevirapine or Efavirenz) during the study period and
treatment was given as per National AIDS Control
Organisation guidelines (NACO Report, 2006). Children
who did not initiate HAART were also monitored every
3 months up to 1 year. The immunological and virological
characteristics of different groups at baseline are
described in Table 1 and during follow-up are described
in Table 2. We also studied 20 (nine males/11 females)
healthy age-matched HIV uninfected children as controls
at one time point only.
Resiquimod induced cytokine expression on DC
subsets
We evaluated the effect of RSQ, a chemical agonist of TLR7
and TLR8, on the DC subsets of HIV+ children. As shown in
Table 2 the absolute number of mDCs was greater than that
of pDCs in both HIV+ and age-matched healthy control
subjects. At baseline, RSQ-induced cytokine expression in
both DC subsets (mDC and pDC) showed considerable
inter-individual variation in both HIV+ children and
age-matched healthy controls. Compared with controls,
HIV+ children had significantly lower percentages of
RSQ-induced TNF-a-producing cells in both DC subsets.
In contrast, IFN-a was expressed exclusively by pDCs and
children with HIV had a significantly lower proportion of
RSQ-induced IFN-a-secreting pDCs than healthy children
(Fig. 2).
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Fig. 1 Flow cytometry gating strategy to detect cytokine production and expression of maturation factors by DCs in whole blood. (a) Among viable
cells, DCs are identified as negative for the lineage markers (Lin-1) and positive for HLA-DR. (b) HLA-DRpos and Lineage-1neg DCs are then
phenotyped as myeloid (CD123low, CD11chigh) or plasmacytoid (CD11clow, CD123high) DCs. (c) Expression of maturation factors (CD83, CD80 and
CCR7) and cytokines (TNF-a and IFN-a) on DC subsets after TLR7/8 stimulation including isotype and unstimulated controls.
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Reduced RSQ-induced cytokine expression persisted
over follow-up with a further decline in IFN-a induction in
pDCs at 12 months (Fig. 3). By contrast, TNF-a expression
on both DC subsets was stable between 0 and 12 months in
all HIV+ children but significantly lower than in controls.
When cytokine expression was compared in patients across
different immune stages (IC-1, IC-2 or IC-3), RSQ-induced
cytokine expression did not correlate significantly with
disease stage. In comparison with untreated subjects,
children initiating HAART exhibited stable expression of
TNF-a in mDCs. By contrast, a profound reduction of TNF-a
and IFN-a expression in pDCs was seen in HIV+ children
even after treatment.
Resiquimod induced DC maturation
To examine the effect of reduced cytokine expression on DC
maturation in HIV+ children, we analysed the expression of
CD83, CD80 and CCR7, all of which are associated with the
maturation status of DCs. As shown in Fig. 4, RSQ-induced
CD80 and CD83 expression was significantly lower in mDCs
of HIV+ children at baseline than controls. In contrast,
RSQ-induced CD80 expression was non-significant in
pDCs. Also, in comparison with age-matched healthy
controls, RSQ-induced CD83 and CCR7 expression was
significantly lower in pDCs of HIV+ children.
The defect in DC maturation persisted over follow-up with
a further decline in the expression of maturation markers
especially CD80 on pDCs at 12 months. CD83, CD80 and
CCR7 expression on pDCs varied greatly among different IC
groups and the group of HIV+ children as a whole during
follow-up. As shown in Fig. 5, RSQ-induced pDC maturation
did not correlate significantly with changes in CD4 T-cell
counts. In comparison with the untreated children, the HIV+
children initiating HAART showed increased expression of
CD83 and CCR7 on pDCs. By contrast, a further decline in
CD80 expression was seen on pDCs in HIV+ children even
after treatment.
Table 1 Baseline immunological and virological characteristics of the study population
Category
Total no. of
HIV subjects IC-1 IC-2 IC-3 Control
No. of samples* 62 20 33 (4) 9 (5) 20
Age† 7 (0.9–13) 7 (0.9–13) 6 (1.5–12) 6 (3–13) 7 (1–12)
VL (log 10) (copies per mL)† 4.96 (3.65–5.87) 4.7 (3.65–5.88) 4.97 (3.75–5.88) 5.32 (4.73–5.69) –
Hemoglobin (g dL1) 10.96  1.4‡ 10.73  1.45 10.96  1.51 11.19  1.23 10.51  1.30
CD3
% 79  10 79  8 78  7 81  14 66  10
Cells per mm3 2878  1439 2954  1079 2899  1374 2780  1864 4131  2791
CD4
% 21  4 32  5 21  3 9  3 33  8
Cells per mm3 766  374 1213  530 809  459 275  132 2147  1452
CD8
% 53  10 42  8 51  8 66  14 29  10
Cells per mm3 1909  1041 1557  578 1885  883 2286  1661 1764 1 446
CD19
% 10  6 12  7 11  5 8  5 23  8
Cells per mm3 388  335 459  375 465  450 240  179 1338  939
CD16+56
% 17  4 5  3 7  6 5  4 9  5
Cells per mm3 220  197 193  130 306  313 161  149 485  389
DC
% 0.36  0.03 0.31  0.13 0.38  0.28 0.40  0.14 0.67  0.32
Cells per mm3 31  2 27  14 31  17 33  18 86  66
mDC
% 0.26  0.02 0.24  0.09 0.26  0.20 0.28  0.09 0.44  0.20
Cells per mm3 22  2 21  11 22  13 23  12 57  43
pDC
% 0.1  0.01 0.07  0.05 0.12  0.10 0.12  0.07 0.23  0.14
Cells per mm3 9  1 6  4 10  6 10  7 29  24
*Values in parentheses are the number of children initiated on HAART.
†Data are median (range).
‡Data are mean  SD.
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Table 2 Immunological and virological changes in different IC groups during follow-up
Baseline 3rd Month 6th Month 9th Month 12th Month
Total
n* 52 (62) 52 (58) 52 (58) 52 (53) 52 (52)
DC
% 0.36  0.03 0.29  0.02 0.39  0.03 0.41  0.02 0.49  0.03
Cells per mm3 31  2 25  2 34  3 34  2 40  3
mDC
% 0.26  0.02 0.22  0.02 0.29  0.02 0.3  0.02 0.38  0.03
Cells per mm3 22  2 18  1 25  2 25  1.41 31  2
pDC
% 0.1  0.01 0.07  0.01 0.10  0.01 0.11  0.01 0.11  0.01
Cells per mm3 9  1 6  1 9  1 9  1 9  1
CD3
% 79  10 81  2 81  1 82  1 79  2
Cells per mm3 2878  1439 3100  198 2963  195 3093  154 2901  172
CD4
% 21  4 25  2 26  1 28  2 26  1
Cells per mm3 766  374 947  63 958  80 1048  77 867  66
CD8
% 53  10 51  2 50  1.6 50  1.92 49  2
Cells per mm3 1909  1041 1953  143 1820  133 1880  111 1694  125
VL (log10) (copies per mL) 4.94 – 4.42 – 4.31
IC-1
n* 18 (20) 18 (20) 18 (20) 18 (18) 18 (18)
DC
% 0.31  0.13 0.30  0.15 0.36  0.14 0.43 0.23 0.53  0.26
Cells per mm3 27  14 25  15 32  19 35  15 42  22
mDC
% 0.24  0.09 0.23  0.14 0.28  0.12 0.34  0.2 0.43  0.23
Cells per mm3 21  11 19  13 24  12 27  12 34  18
pDC
% 0.07  0.05 0.07  0.03 0.08  0.05 0.09  0.04 0.10  0.06
Cells per mm3 6  4 6  3 8  7 7  4 8  5
CD3
% 79  8 83  7 82  6 81  6 78  9
Cells per mm3 2954  1079 2736  870 2789  1410 2743  1073 2365  774
CD4
% 32  5 33  7 31  5 34  7 34  8
Cells per mm3 1213  530 1086  395 1068  619 1150  549 1033  448
CD8
% 42  8 46  9 46  9 43  11 40  11
Cells per mm3 1557  578 1517  548 1560  802 1461  703 1197  437
VL (log10) (copies per mL) 4.7 – 4.73 – 4.53
IC-2
n* 22 (33) 22 (25) 22 (25) 22 (22) 22 (22)
DC
% 0.38  0.28 0.27  0.15 0.43  0.24 0.38  0.10 0.49  0.25
Cells per mm3 31  17 22  12 30  12 35  11 40  22
mDC
% 0.26  0.20 0.2  0.13 0.32  0.21 0.26  0.07 0.39  0.21
Cells per mm3 22  13 17  9 22  8 24  9 31  13
pDC
% 0.12  0.10 0.07  0.05 0.10  0.05 0.12  0.06 0.10  0.07
Cells per mm3 10  6 6  4 8  5 11  4 9  6
CD3
% 78  7 80  9 79  9 82  9 79  12
Cells per mm3 2899  1374 3546  2039 2639  1243 3608  1237 2830  1316
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We observed significantly lower expression of CD83 and
CD80 on mDCs in the group of HIV+ children as well as
different IC groups and during follow-up. As shown in Fig. 6,
expression of CD83 and CD80 on mDCs varied greatly in
HIV+ children but was significantly lower than in controls. In
comparison with the untreated children, HIV+ children
Table 2 (continued)
Baseline 3rd Month 6th Month 9th Month 12th Month
CD4
% 21  3 21  2 21  3 20  3 19  3
Cells per mm3 809  459 933  510 692  326 909  451 684  286
CD8
% 51  8 53  10 53  9 58  11 55  11
Cells per mm3 1885  883 2341  1411 1757  853 2488  738 2008  1048
VL (log10) (copies per mL) 5.0 – 4.63 – 4.6
IC-3
n* 4 (9) 4 (4) 4 (4) 4 (4) 4 (4)
DC
% 0.40  0.14 0.37  0.06 0.42  0.39 0.47  0.12 0.57  0.10
Cells per mm3 33  18 26  12 51  35 36  10 51  22
mDC
% 0.28  0.09 0.26  0.06 0.28  0.26 0.33  0.13 0.40  0.08
Cells per mm3 23  12 18  9 31  27 26  10 36  15
pDC
% 0.12  0.07 0.11  0.04 0.14  0.10 0.14  0.03 0.16  0.03
Cells per mm3 10  7 8  5 19.89  8.13 11  3 15  7
CD3
% 81  14 77  20 87  6 84  6 79  10
Cells per mm3 2780  1864 2424  1413 4691  1652 2492  435 2329  1022
CD4
% 9  3 12  2 13  2 12  2 11  3
Cells per mm3 275  132 357  177 670  158 376  118 348  185
CD8
% 66  14 60  18 68  8 67  8 63  12
Cells per mm3 2286  1661 1923  1190 3766  1663 1988  341 1846  805
VL (log10) (copies per mL) 5.24 – 5.48 – 5.23
HAART
n* 8† (9) 8 (9) 8 (9) 8 (9) 8 (8)
DC
% 0.42  0.25 0.28  0.15 0.44  0.17 0.40  0.08 0.34  0.04
Cells per mm3 33  28 27  18 36  22 32  3 27  6
mDC
% 0.31  0.17 0.21  0.08 0.31  0.13 0.31  0.02 0.24  0.03
Cells per mm3 25  19 20  11 27  19 26  7 19  4
pDC
% 0.11  0.08 0.07  0.08 0.13  0.05 0.09  0.07 0.1  0.05
Cells per mm3 9  9 7  7 9  4 6  4 8  3
CD3
% 75  14 83  4 81  8 83  4 80  3
Cells per mm3 2969  1808 3103  994 3190  1185 3122  1160 2686  545
CD4
% 13  2 25  2 24  6 34  7 30  3
Cells per mm3 477  156 906  185 1059  351 1303  489 942  99
CD8
% 55  16 53  7 53  8 45  10 44  3
Cells per mm3 2243  1596 1991  740 1963  888 1681  978 1564  408
VL‡ (log10) (copies per mL) 5.5 – 3.25 – 3.01
*Number of samples taken for analysis (total number of samples collected).
†Before initiation of HAART (data are mean  SD).
‡VL, viral load (data are median values).
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initiating HAART showed a non-significantly higher expres-
sion of CD83 and CD80 on mDCs.
Discussion
We studied DC-specific markers of phenotype and function
in children with perinatal HIV infection and evaluated their
change over a period of 1 year. We also compared these
markers across different CD4 strata and studied the impact
of HAART on DC functions and phenotype.
Although previous research has shown that HIV-1-
infected individuals have reduced mDC and pDC levels,
information on the functional capability of blood DC subsets
and their role during immune reconstitution in HA-
ART-treated pediatric HIV patients is not well described
(Zhang et al., 2006; Usuga et al., 2008). We found that
circulating mDCs and pDCs were deficient qualitatively and
quantitatively at study entry in HIV-infected children when
compared with age-matched controls. The persistence of
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these defects over 1 year, with a further decline in some of
their characteristics, suggests that these functional proper-
ties may play an important role in mounting or maintaining a
successful immune response against perinatal HIV infec-
tion. We also found that HAART treatment partially restored
mDCs, but that recovery of pDCs was incomplete. Our data
showing a further decline in CD80 and IFN-a induction in
pDCs over follow-up, despite HAART, supports the idea that
pDC function is profoundly impaired in pediatric patients with
HIV-1 infection and that delayed HAART initiation does not
restore this immunological defect. Collectively, these
defects were evident in analysis of all patients, and were
variably expressed in patients in immune categories IC-1,
IC-2 and IC-3.
In agreement with studies conducted in adult populations
(Macatonia et al., 1990; Grassi et al., 1999; Feldman et al.,
2001; Chehimi et al., 2002; Hemmi et al., 2002; Barron
et al., 2003; Donaghy et al., 2003), both mDC percentages
and their ability for cytokine (TNF-a) production were
reduced in therapy na€ıve HIV-infected children, indicating
that this DC subset is also depleted in pediatric HIV-1
infection. The functional impairment of mDCs partially
recovered in children on HAART. The differential restoration
of mDCs and pDCs in HIV-1-infected children after HAART
might be explained in part by differences in HIV suscepti-
bility, variable sensitivities to HAART treatment, and selec-
tive interaction of HIV-1 with mDCs and pDCs.
Based on our examination of circulating DC subsets
throughout the period of our study, we draw the following
conclusions. First, HIV-1 infection leads to a decrease in
numbers of circulating DC subsets along with a functional
impairment in these cells. Impaired functions include the
Compared to healthy controls
Compared to baseline
Healthy control
HIV patients baseline
HIV patients at 12 mon
0
20
40
60
80
Without ART
CD83 in pDC
%
 
CD
83
 e
xp
re
ss
io
n
HC Total IC 1 IC 2 IC 3 HAART
Treated
(a)
0
10
20
30
40
50 Without ART
CD80 in pDC
%
 
CD
80
 e
xp
re
ss
io
n
HC Total IC 1 IC 2 IC 3 HAART
Treated
(b)
0
20
40
60
80 Without ART
CCR7 in pDC
%
 
CC
R7
 e
xp
re
ss
io
n
HC Total IC 1 IC 2 IC 3 HAART
Treated
(c)
Fig. 5 Expression of (a) CD83, (b) CD80 and (c) CCR7 on pDC subsets after TLR7/8 stimulation in whole blood taken from age-matched controls,
HIV+ children at baseline, HIV+ children at 12 months follow-up without treatment (categorized as IC-1, IC-2 and IC-3) and HIV+ children at 12 months
after HAART. Whole blood was incubated without any stimulus or with resiquimod (10 µM) for 5 h. Cells were then processed and acquired by flow
cytometry as described in the Methods. The data are shown as the mean and SD.
Compared to healthy controls
Compared to baseline
Healthy control
HIV patients baseline
HIV patients at 12 mon
0
20
40
60
80 Without ART With ART
CD83 in mDC
%
 C
D8
3 
ex
pr
es
si
on
HC Total IC 1 IC 2 IC 3 HAART
Treated
(a)
0
10
20
30
40
50
60
Without ART
CD80 in mDC
%
 C
D8
0 
ex
pr
es
si
on
HC Total IC 1 IC 2 IC 3 HAART
Treated
(b)
Fig. 6 Expression of (a) CD83 and (b) CD80 on mDC subsets after TLR7/8 stimulation in whole blood taken from age-matched controls, HIV+ children
at baseline, HIV+ children at 12 months follow-up without treatment (categorized as IC-1, IC-2 and IC-3) and HIV+ children at 12 months after HAART.
Whole blood was incubated without any stimulus or with resiquimod (10 µM) for 5 h. Cells were then processed and acquired by flow cytometry as
described in the Methods. The data are shown as the mean and SD.
Pathogens and Disease (2013), 69, 184–193, © 2013 Federation of European Microbiological Societies. Published by John Wiley & Sons Ltd. All rights reserved 191
A. Selvaraj et al. Defective dendritic cell response in HIV-infected children
decreased expression of maturation markers (CD80, CD83
and CCR7) and decreased cytokine-releasing capacities of
mDCs (TNF-a) and pDCs (TNF a and IFN-a). Secondly,
while HAART can successfully control HIV-1 replication,
there is only a partial recovery in DCs; pDC frequency and
function recovery is less than mDC recovery. Time of
initiation of HAART may influence the degree of recovery of
functionally impaired pDCs, as most children in this cohort
started treatment quite late. Thus, cellular immune
responses that involve CD4 T cells may be induced,
coordinated and regulated by DCs.
The cohort studied by us were children who had survived
infancy and thus had a less aggressive course of the
disease (Fig. 7). Furthermore, only a small number were
initiated on HAART during the 12-month period of follow-up,
limiting our observation on the impact of HAART on
recovery of innate immune functions. However, future
studies are planned to examine this phenomenon in infants
initiated on HAART early in life, and examine the long-term
effect of HAART on the immune system.
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